Health
Eli Lilly
Live from the archive on 20 September 2026. File S01E98 investigates Eli Lilly and the diabesity ecosystem, tracking how a pharmaceutical giant turned the absence of hunger into a highly collateralized commodity.
Eli Lilly
Eli Lilly isn't just selling weight-loss drugs; they're running a subscription model for human biology. A critical look at the compounding pharmacy black market, regulatory gridlock, and the cynical reality of lifelong dependency pricing.
Eli Lilly
An analytical breakdown of Eli Lilly's GLP-1 portfolio, examining how chemical appetite suppression is driving a macroeconomic migration of capital from the global food industry to the pharmaceutical sector amid shifting Medicare coverage.
Novo Nordisk
File open 18 September 2026: Novo Nordisk / Diabesity Ecosystem.
Novo Nordisk
Marcus on Novo Nordisk: the spin vs the invoice.
Novo Nordisk
Forensic audit of Novo Nordisk under Diabesity Ecosystem.
Medtronic
File open 17 September 2026: Medtronic / Neuro-Modulation.
Medtronic
Marcus on Medtronic: the spin vs the invoice.
Medtronic
Forensic audit of Medtronic under Neuro-Modulation.
Cassandra Protocol
On 14 September 2026, the Cassandra Archive opens the ledger on Boston Scientific's neuromodulation market. Discover the financialization of the human nervous system in this cyberpunk audio drama.
Medical Device Failure
Boston Scientific isn't curing pain; they are leasing your nervous system. A critical look into the rapid degradation of lithium-ion spinal implants and the dark reality of recurring surgical revenue.
Boston Scientific
An analytical review of Boston Scientific's neuromodulation devices, focusing on the clinical efficacy and scheduled engineering lifecycles of implantable spinal cord stimulators for chronic pain management.